Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes

Diabetes Technology and Therapeutics

Volumn 10, Issue 5, 2008, Pages 363-368

  Chandra, Satish T ^a   Priya, Gagan ^a   Khurana, Madan L ^a   Jyotsna, Viveka P ^a   Sreenivas, V ^a   Dwivedi, Sadanand ^a   Ammini, Ariachery C ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CHOLESTEROL; GLICLAZIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; DISEASE DURATION; DRUG EFFICACY; EVENING DOSAGE; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; KETONURIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REMISSION; SINGLE DRUG DOSE; STATISTICAL ANALYSIS;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 50049134419     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0045     Document Type: Article

References (35)

1. Peck FB Jr, Kirtley WR, Peck FB Sr: Complete remission of severe diabetes. Diabetes 1958;7:93-97.
2. Genuth SM: Clinical remission of diabetes mellitus. Studies of insulin secretion. Diabetes 1970;19:116-121.
3. Stutman LJ, Hayes JD: Severe diabetes with remission, report of a case. Diabetes 1959;8:189-191.
4. Harwood R: Severe diabetes with remission; report of a case and review of the literature. N Engl J Med 1957;257:257-261.
5. Hines JJ, Kessler DL: Unexplained remission of long standing severe diabetes mellitus. Ann Intern Med 1961;55:314-316.
6. Banerji MA: Diabetes in African-Americans: unique pathophysiologic features. Curr Diabetes Rep 2004;4:219-223.
7. Umpierrez GE, Casals MM, Gebhart SP, Mixon PS, Clark WS, Phillips LS: Diabetic ketoacidosis in obese African-Americans. Diabetes 1995;44:790-795.
8. Nagasaka S, Ishikawa S, Itabashi N, Rokkaku K, Saito T: Ketoacidosis-onset type 2 diabetes in Japanese. Association with the widespread distribution of soft drinks and vending machines. Diabetes Care 1998;21:1376-1378.
9. Umpierrez GE, Smiley D, Kitabchi AE: Ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006;144:350-357.
10. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA: Near-normoglycaemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10-16.
11. Banerji MA, Chaiken RL, Lebovitz HE: Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. Diabetes 1996;45:337-341.
12. Kayashima T, Yamaguchi K, Konno Y, Nanimatsu H, Aragaki S, Shichiri M: Effects of early introduction of intensive insulin therapy on clinical course in non-obese NIDDM patients. Diabetes Res Clin Pract 1995;28:119-125.
13. Bloom A: Remission in diabetes. BMJ 1959;2:731-734.
14. Crowley MF, Wolff FW, Bloom A: Tolbutamide in diabetes: some clinical and biochemical studies. BMJ 1957;2:327-331.
15. Lev-Ran A: Trial of placebo in long-term chlorpropamide-treated diabetics. Diabetologia 1974;10:197-200.
16. Ryan EA, Imes S, Wallace C: Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004;27:1028-1032.
17. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care 2004;27:2597-2602.
18. Shikha S, Khurana ML, Ammini AC: Long term remission following initial insulin therapy in type 2 diabetes: report of 3 cases. Presented at North American Association for the Study of Obesity 2003 Annual Scientific Meeting, October 11-15, 2003, Ft. Lauderdale, FL.
19. Firth RG, Bell PM, Rizza RA: Effects of tolazamide and exogenous insulin on insulin action in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1986;314:1280-1286.
20. Samanta A, Burden AC, Kinghorn HA: A comparative study of sulphonylurea and insulin therapy in non-insulin dependent diabetics who had failed on diet therapy alone. Diabetes Res 1987;4:183-185.
21. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983;24:404-411.
22. U.K. Prospective Diabetes Study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study. Diabetes 1985;34:793-798.
23. Wolffenbuttel BH, Weber RF, van Koetsveld PM, Weeks L, Verschoor L: A randomized crossover study of sulphonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. Diabet Med 1989;6:520-525.
24. Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Forbes EF, Steen L, Westermark G, Westermark P, Orn T, Grill V: Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care 2003;26:2231-2237.
25. Rahier J, Goebbels RM, Henquin JC: Cellular composition of the human diabetic pancreas. Diabetologia 1983;24:366-371.
26. Porte D Jr: Banting Lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991;40:166-180.
27. Masiello P, Novelli M, Fierrabracci V, Bergamini E: Protection by 3-aminobenzamide and nicotinamide against streptozocin-induced beta-cell toxicity in vivo and in vitro. Res Commun Chem Pathol Pharmacol 1990;69:17-32.
28. Zhou YS, Gao Y, Guo XH, Li B, Wang S, Chi JM: Effects of timely insulin treatment on protection of β cells in a rat model of type 2 diabetes mellitus. Chin Med J (Engl) 2004;117:1523-1529.
29. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 1984;33:634-642.
30. Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC: Changes in amylin and amylin-like peptide concentrations and β-cell function in response to sulfonylurea or insulin therapy in NIDDM. Diabetes Care 1998;21:810-816.
31. 2+ concentration. J Biol Chem 1998;273:33501-33507.
32. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY: Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005;90:501-506.
33. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-1356.
34. Banerji MA, Lebovitz HE: Remission in non-insulin-dependent diabetes mellitus: clinical characteristics of remission and relapse in black patients. Medicine (Baltimore) 1990;69:176-185.
35. Pocai A, Lam TKT, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, Aguilar-Bryan L, Rossetti L: Hypothalamic KATP channels control hepatic glucose production. Nature 2005;434:1026-1031.